Donald Tindall

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Symposium on androgen action in prostate cancer
    Donald Tindall
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 64:7178-80. 2004
  2. ncbi Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 95:1028-36. 2002
  3. ncbi Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial
    Gerald Andriole
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Urol 172:1314-7. 2004

Detail Information

Publications3

  1. ncbi Symposium on androgen action in prostate cancer
    Donald Tindall
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 64:7178-80. 2004
  2. ncbi Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 95:1028-36. 2002
    ..The objective of this study was to examine the clinical and pathologic features of metastatic prostate carcinoma to bone in a large cohort of men, and the associations of these features with outcome...
  3. ncbi Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial
    Gerald Andriole
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Urol 172:1314-7. 2004
    ..It represents a biologically plausible target for chemoprevention through the inhibition of 5alpha-reductase isoenzymes...